ADAG
AdageneยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ADAG Profile
Adagene Inc.
A clinical-stage biotechnology company that develops antibody therapeutics for the treatment of cancer
Pharmaceutical
02/25/2011
02/09/2021
NASDAQ Stock Exchange
138
12-31
Depository Receipts (Ordinary Shares)
4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, 215123, People's Republic of China
Research, development and production of cancer monoclonal antibody drugs
Tianyan Pharmaceutical is a limited liability company incorporated in the Cayman Islands on February 25, 2011. They are a private, global, clinical-stage immunotherapy company that redefines antibody discovery and design, opening up new frontiers for cancer treatment. Driven by a powerful platform that combines computational biology and artificial intelligence, they have created new antibodies that overcome safety issues. Improve efficacy and bring hope to more cancer patients. Their discovery engine, Dynamic Precision Library, is pushing Adagene's array of programs into potentially best-in-class or best-in-class programs. They have established strategic partnerships with a number of well-known global companies. These partnerships apply their technologies to the frontiers of science, including safer precision-guided antibody-drug conjugates, transformational antibody designs and advanced CAR constructs to address significant unmet needs. Founded and led by world-class leaders in antibody discovery and engineering, they have raised more than $150 million from well-known investors. In areas where other treatments have had little or no success, Adagene is well positioned to meet unmet needs.
